MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited Interest Expense 2011-2026 | VNRX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -233 K | 311 K | - | - | 130 K | 127 K | -111 K | 73.1 K | 20.4 K | -15.7 K | 14.8 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 311 K | -233 K | 35.1 K |
Quarterly Interest Expense VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -309 K | -16.3 K | 45.1 K | - | 129 | -69.8 K | - | - | - | - | - | - | - | - | 41 K | - | 38.8 K | 39.7 K | 42.2 K | - | 34.7 K | 22.6 K | 33.8 K | - | 32.3 K | 33.1 K | -30.1 K | - | -29.1 K | 26.6 K | 23 K | - | 17.6 K | 20.4 K | 12.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 45.1 K | -309 K | 437 |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
81 M | $ 119.04 | 0.74 % | $ 36.2 B |  USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.83 | -4.39 % | $ 91.8 K | USA |
 |
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 23.54 | -6.44 % | $ 247 M |  China |
 |
Celcuity
CELC
|
2.11 M | $ 107.4 | -0.83 % | $ 4.24 B | USA |
|
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
1 K | $ 27.57 | -1.5 % | $ 766 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 175.69 | -1.63 % | $ 8.71 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 13.79 | -2.89 % | $ 417 M | USA |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
8.26 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
56.7 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.12 | -1.75 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 208.36 | -0.91 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 204.01 | -0.91 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 103.37 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
1.29 M | $ 8.74 | -0.34 % | $ 548 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
177 M | $ 73.08 | -0.95 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
17 K | - | -1.84 % | $ 15.3 M | USA |
 |
QIAGEN N.V.
QGEN
|
-739 K | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
2.72 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 108.7 | 0.4 % | $ 8.97 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 635.54 | -0.18 % | $ 51.1 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 129.56 | -2.51 % | $ 20.6 B | USA |
 |
Renalytix AI plc
RNLX
|
249 K | - | 5.66 % | $ 22.7 M |  Britain |
 |
CareDx, Inc
CDNA
|
524 K | $ 18.8 | 0.29 % | $ 1 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
13 K | - | - | $ 9.42 M | Israel |
 |
Guardant Health
GH
|
-10.5 M | $ 93.3 | 1.16 % | $ 11.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 282.99 | -1.21 % | $ 23.5 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 78.84 | 3.33 % | $ 5.32 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 173.96 | -0.18 % | $ 29.9 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | - | - | $ 79.8 M | USA |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 37.72 | -3.43 % | $ 1.92 B | USA |